Laboratory Monitoring After Kcentra Infusion

Immediate Post-Infusion Testing (15-60 Minutes)

Obtain an INR within 15-60 minutes after Kcentra administration to confirm adequate reversal, followed by repeat INR testing at 12-24 hours to detect rebound coagulopathy, with a target INR typically <1.5 for most bleeding scenarios, though some protocols aim for <1.3 in intracranial hemorrhage 1
If the repeat INR remains ≥1.4, consider administering fresh frozen plasma (FFP) or additional reversal agents 1

Repeat INR at 12-24 hours after initial administration to detect rebound increases in anticoagulation, as rebound coagulopathy can occur if vitamin K was not co-administered with Kcentra 1

Always administer intravenous vitamin K (5-10 mg) concurrently with Kcentra to prevent later INR increases, as PCC alone provides only temporary reversal 1
Consider checking hemoglobin/hematocrit to assess ongoing bleeding and transfusion requirements 2
Monitor for thrombotic complications clinically, as repeat PCC dosing increases risk of disseminated intravascular coagulation (DIC) 1

Do not delay Kcentra administration while waiting for initial INR results in life-threatening bleeding—treat based on clinical suspicion of significant anticoagulation 1
Post-reversal INR testing allows for timely surgical intervention when needed, as procedures can proceed once adequate reversal is confirmed 1

Failing to check early post-infusion INR (within 1 hour) prevents identification of inadequate reversal requiring additional intervention 1
Omitting vitamin K administration leads to rebound coagulopathy as PCC effects wear off while warfarin remains active 1
Not performing 12-24 hour follow-up INR misses delayed rebound increases in anticoagulation 1
Waiting for laboratory confirmation before treating in life-threatening bleeding delays critical therapy—initiate reversal immediately based on clinical assessment 1